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Background: Osteoarthritis (OA) is defined by signs and symptoms of inflammation within the affected joint. The aim
of this study is to determine the mRNA expression levels of selected cytokines and matrix-metalloproteinases of cells
found in synovial fluid (SF) obtained from osteoarthritic knee joints compared to healthy controls.
Methods: SF was obtained from 40 patients undergoing total knee arthroplasty due to evident OA and from 10
healthy controls. Expression of TNF-α, IL-1β, MMP-1 and MMP-3 was assayed among both groups by performing
qPCR. Patients were configured concerning age, gender and BMI.
Results: IL-1β, MMP-1 and MMP-3 showed significantly higher expression among the OA group compared to
control (P < 0.001). Strong correlation appeared between expression of MMP-1 and MMP-3 among OA patients
(r = 0.856); no correlation was found between age, gender or BMI and cytokine/proteinase expression. Expression
of IL-1β, MMP-1 and MMP-3 within SF was elevated in OA-patients.
Conclusion: Consequently, cells within SF expressing cytokines and proteinases may play a relevant role in the
progression of joint destruction. Considering the fact that SF in an OA joint comprises abnormal amounts of
detrimental bioactive proteins, temporary clearance, dilution or suppression/modulation by means of lavage or
disease-modifying medication may be promising to constitute interim relief or even postpone disease progression due
to decreased inflammatory and/or degrading activity within the articular environment.
Keywords: Cytokines, Proteinases, Osteoarthritis, Cartilage, Synovial fluid, BiomarkersBackground
Osteoarthritis (OA) is characterized by slowly progressing
destruction of the articular cartilage as well as an inflam-
matory reaction within the realms of the affected joint [1].
OA represents the most common joint disorder in the
world and results in pain, deformity and gradual loss of
joint function [1-3]. The origin includes mechanical injury,
genetic factors and aging [4]. Disease progression is
characterized by formation of osteophytes, subchondral
bone cysts, increased thickness of the subchondral bone* Correspondence: sauerschnig@gmail.com
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article, unless otherwise stated.plate and loss of articular cartilage [5]. The exact etiology
of OA, however, is not fully understood.
Synovial inflammation is commonly found in early stage
OA and is characterized by joint swelling, redness, heat
and pain [6,7]. The synovium is infiltrated by an increased
number of synovial lining cells and immune cells such as
macrophages, mast cells, T- and B-lymphocytes and
plasma cells. Activated synovial cells, immune cells
and chondrocytes produce large quantities of matrix me-
talloproteinases (MMPs) -1, -3, -9, -13 and ADAMTS, a
disintegrin and metalloproteinase with thrombospondin
motifs [8]. These proteolytic enzymes eventually degrade
extracellular matrix macromolecules and cause a loss of
cartilage integrity and biomechanical strength [9-11].
Proinflammatory cytokines act as soluble mediators
and favor catabolic activities in articular cartilage [12,13].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cells while their specific origin in OA, however, is still
unclear [14]. The proinflammatory cytokines IL-1β and
TNF-α are found in elevated concentration in synovial
fluid (SF) and joint tissue of OA patients. Both activate
the JNK, p38 MAPK and NF-κB signaling pathways in
chondrocytes [15,16]. They are capable of suppressing
proteoglycan, collagen II and aggrecan expression while
stimulating MMP expression and the production of
further catabolic cytokines such as IL-6, IL-8, MCP-1
and CCL-5 [17].
OA is no longer understood as a disease merely caused
by wear and tear but rather as an inflammatory process
[18]. Definition of baseline cytokine and proteinase
levels and their mRNA concentration in SF of healthy
and OA patients is crucial to evaluate the potential for
diagnosing early OA using cytokines as biomarkers [19].
The objective of this study was to elucidate whether the
cells in the SF are producing the detrimental proteins
mentioned above. Thus, we aimed to quantify mRNA
expression patterns of the main inflammatory mediators
IL-1β and TNF-α and degradative enzymes MMP-1 and
MMP-3 within synovial fluid of OA patients compared
to healthy controls. Such information would further
define the role of the mentioned cytokines and proteases
within the complex cascades of incidental/progressive
OA and could strengthen their potential as biomarkers
and/or novel therapeutic targets.
Methods
Patients and donors
Patient and donor characteristics are presented in Table 1.
A total of 40 patients (18 females, 22 males) with clinically
as well as radiographically-evident OA were included
and SF was obtained prior to total knee arthroplasty
(TKA). Furthermore, SF was obtained from a total ofTable 1 Osteoarthritis (OA) patient and control
characteristics
OA patients Control (donors) Total
Gender
Male 22 6 28
Female 18 4 22
Total 40 10 50
Age
Mean 67.88 ± 10.56 51.4 ± 6.36 64.58 ± 11.86
Range 39 to 99 42 to 62 39 to 99
Body Mass Index
Mean 29.28 ± 5.77 25.26 ± 1.93 28.48 ± 5.47
Range 21.1 to 44.2 22.2 to 28.3 21.1 to 44.2
Gender (male/female), age and body mass index (BMI) at the time of
examination among OA patients and controls, mean ± SD. Significance
provided within results section.10 controls/donors (4 females, 6 males) with no history of
joint surgery or any cartilage/OA-related disease, within
4 hours after death due to insult or atraumatic intracranial
bleeding. SF harvesting among patients as well as
controls was performed utilizing a sterile syringe with
the needle injected into the knee joint using a standardized
anterolateral portal, strictly avoiding hemarthrosis. Single
incision arthrotomy allowed then for direct visualization of
the knee joint and cartilage evaluation was performed by an
experienced orthopedic surgeon in order to exclude the
presence of OA.
The study was performed in accordance with the
Declaration of Helsinki. Informed consent from each
patient as well as approval from the local ethics committee
was obtained prior to investigation (Ethics commission,
Charité, Berlin, EA1/083/09).
RNA extraction
After centrifugation of SF from OA patients and controls
directly after harvest, the cell-pellet was disrupted in
RA-1 lysis buffer (Macherey-Nagel, Düren, Germany)
and stored at −80°C until further analysis. Total RNA
was then isolated from the cell-pellet yielded using the
NucleoSpin RNA II® kit (Macherey-Nagel, Düren,
Germany) according to the manufacturer’s protocol.
Reverse transcription
A volume of 8 μl mRNA template, 1 μl 10 mM
Deoxynucleotide-Mix (dNTP-Mix, Invitrogen Life Tech-
nologies, Paisley, UK) and 1 μl random primer (Invitrogen
Life Technologies, Paisley, UK) was incubated for 5 minutes
at 65°C in a thermocycler (Eppendorf, Hamburg, Germany)
and then cooled down to 4°C. A total of 9.5 μl reaction
mix consisting of 4 μl reaction buffer (M-MLV RT 5x
Reaktionspuffer, Promega GmbH, Mannheim, Deutschland),
1 μl RNase inhibitor (RNase Inhibitor 40 U/μl, Promega
GmbH, Mannheim, Deutschland) and 4.5 μl H2O were
added and incubated at 42°C for 2 minutes. After adding
1 μl of reverse transcriptase (M-MLV RT(H-) 200 U/μl,
Promega GmbH, Mannheim, Deutschland), an incuba-
tion period of 50 minutes at 42°C was followed by
15 minutes at 70°C, producing the cDNA to be further
analyzed via qPCR. After cooling to 4°C, residual RNA
was eliminated using 1 μl of RNase (RNse H 250 U/μl,
Promega GmbH, Mannheim, Deutschland) for 20 minutes
at 37°C.
Quantitative polymerase chain reaction (qRT-PCR)
Expression profiles were assessed via qRT-PCR on an
iCycler detection system (Bio-Rad, Munich, Germany) using
SYBR Green (Applied Biosystems, Foster City, CA, USA) as
a fluorescent reporter. Primers were designed by TIB
MOLBIOL (Syntheselabor GmbH, Berlin, Germany) and
tested with the Basic Local Alignment Search Tool
Table 2 Expression levels in osteoarthritis (OA) patients
and controls
Median Interquartile range P-value
25 75
MMP-1 OA SF 1.48 0.71 3.77 < 0.001
Donor SF < 0.01 < 0.01 < 0.01
MMP-3 OA SF 3.78 1.49 8.64 < 0.001
Donor SF < 0.0 < 0.01 < 0.01
IL-1β OA SF 1.41 0.72 4.09 < 0.001
Donor SF < 0.01 < 0.01 1.91
TNF-α OA SF 2.57 1.22 5.59 0.077
Donor SF < 0.01 < 0.01 6.27
Detectable expression levels of MMP-1, MMP-3, IL-1β and TNF-α within synovial
fluid (SF) yield from affected patients (OA) and controls. Median and interquartile
ranges (IQR: 25th to 75th percentile) are reported to depict differences
in distribution.
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The 25 μl reaction-mix consisted of 1.0 μl cDNA
template, 12.5 μl iQ Supermix (Bio-Rad, Munich, Germany),
0.5 μl primer forward (10 μM), 0.5 μl primer reverse
(10 μM), 1.0 μl SYBR-Green (Applied Biosystems, Foster
City, CA, USA) and 9.5 μl DNase-free water. iCycler
settings involved activation of the polymerase reaction at
95°C (15 minutes), followed by 38 cycles of denaturation
at 94°C (30 seconds), primer annealing at 59°C according
to primer-specific requirements (40 seconds), elongation
at 72°C (30 seconds) and fluorescence detection at 80°C
(15 seconds). GAPDH was used as an internal control and
all reactions were performed in triplicates followed by a
specific melting curve analysis of each assay at 60°C
to 95°C (30 seconds). Quantification of mRNA expression
was assessed by the 2- ΔΔCT method [20].
Statistics
The major determinant for outcome comparison was the
expression level of the targeted cytokines and proteases
according to the groups described above. Statistical
analysis was performed using the software package SPSS
version 17 (SPSS Inc., Chicago, IL, USA). All data were
tested for normal distribution using the Kolmogorov-
Smirnov test. The Mann-Whitney U-test was performed
to assess differences in expression levels between groups
corrected for cofounding variables (age, gender, BMI).
Furthermore, Fisher’s exact test was conducted to
compare the frequency of detectable expressions between
the groups. To control the family-wise error rate, the
Bonferroni correction was applied. Unless stated other-
wise, descriptive results were demonstrated as the mean ±




An overview of participant characteristics is given in
Table 1. All patients showed clinically and radiographically-
evident knee OA. Controls showed no history of knee-
related pathologies and there was no intraarticular, noligamentous and particularly no meniscal or cartilage
pathology to be found in any control knee joint and the
surrounding soft tissues were also without pathological
findings. There was a significant overall group difference
for age and BMI (P < 0.05) between groups.
qPCR outcome
IL-1β, MMP-1 and MMP-3 showed significantly higher
expression levels among the OA group compared to the
control (P < 0.001) while TNF-α expression differences
never reached the level of significance (P = 0.077). Median
and interquartile ranges (IQR: 25th to 75th percentile) are
reported to depict differences in distribution of MMP-1,
MMP-3, IL-1β and TNF-α between patients and donors/
controls and an overview is given in Table 2.
Frequency of detectable expression was 85.4% (OA)
versus 0% (control) for MMP-1, 97.6% (OA) versus
12.5% (control) for MMP-3, 95.1% (OA) versus 25.0%
(control) for IL-1β and 95.1% (OA) versus 37.5% (control)
for TNF-α; the corresponding bar charts are given in
Figure 1.
Furthermore, a strong correlation appeared between
expression levels of MMP-1 and MMP-3 among OA
patients (r = 0.856) while no such correlation was found
between age, gender or BMI and the expression levels
investigated.
Discussion
Inflammation plays a pivotal role in the pathogenesis of
OA [4]. However, the cellular origin of inflammatory
mediators and catabolic enzymes remains an area of
speculation [14]. The aim of this study was to quantify
and compare inflammatory and degradative markers on
mRNA levels in cells floating in the SF of OA patients and
healthy controls. The selection of TNF-α, IL-1β, MMP-1
and MMP-3 represents well-established inflammatory
Figure 1 Frequency of detectable expressions of MMP-1, MMP-3, IL-1β and TNF-α within synovial fluid (SF) yield from affected patients
(OA) and controls. Corresponding bar charts are provided with 95% confidence intervals.
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present study demonstrates that there is significantly more
IL-1β, MMP-1 and MMP-3 mRNA transcribed in SF cells
of OA patients compared to healthy controls. The mean
age of OA patients was slightly older compared to the
donor group and older age could lead to a different
onset of inflammatory response. Furthermore, there
was a difference in mean BMI comparing OA patients and
donors. Higher BMI causes higher joint load and one
could imagine that this might interfere with the inflamma-
tory response of the investigated joints. However, the im-
mense differences between the two groups concerning
frequencies of detectable expression of IL-1β, MMP-1 and
MMP-3 are not likely to be caused by the slight differences
of patient age or BMI.
Increased levels of active IL-1β have already been
found in SF of OA patients using ELISA [21-24]. Similar
findings were made analyzing OA cartilage and synovial
tissue using immunohistochemistry [25-27]. To our
knowledge, this is the first study to analyze mRNA levels
of IL-1β in SF cells of OA patients. Our data demonstrate
a high inflammatory activity of SF cells via IL-1β.
However, it is not clear to what extent these cells act
synergistically with cells within the synovial tissue and
cartilage. Furthermore, IL-1β’s mRNA still has to be
translated and IL-1β’s inflammatory potential is influenced
by the presence of IL-1β-converting enzyme, allocation of
suitable receptors and other inflammatory processes. Our
analysis of TNF-α mRNA concentration showed a wide
range of results within the group of healthy controls and
no significant difference to our OA group (P = 0.077).Although TNF-α is accepted as one of the two most
important inflammatory cytokines in OA today, conflicting
reports are found in the literature. Early studies showed
highly inconsistent levels of TNF-α expression in SF and
synovial tissue of OA patients [24,28-30]. Furthermore,
TNF-α levels in SF significantly correlate with clinical
symptoms but not with radiographic findings of OA
[31]. An answer to these contrary reports might be
variations in number and susceptibility of chondrocyte
TNF-α receptors, the presence of soluble TNF-α re-
ceptors and activity of TNF-α-converting enzymes
[24]. Alternatively, TNF-α-expressing cells such as
macrophages could mainly be localized in the syn-
ovial tissue [32].
IL-1β and TNF-α stimulate the production of cartilage-
degrading enzymes [33,34]. As such, MMPs are of
particular interest because they are considered as the
major degradative enzymes in OA [11]. Augmented MMP
levels were found in SF of OA patients and they are
expressed by lining cells, neutrophils, macrophages and
chondrocytes in the synovial tissue [35-38]. Moreover, our
data indicate that a significant amount of MMPs is present
within the synovial fluid. Again, it is not clear whether
these MMPs are produced by cells in the surrounding
tissues or by cells within SF. First and foremost, our data
indicate that cells in the SF are significant contributors.
Thus, this study gives valuable information about potential
treatment options including replacement of SF. Arthro-
scopic joint irrigation has been reported to cause significant
release of pain in early studies. Livesely and colleagues
showed more pain relief after arthroscopic lavage and
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contrast, Moseley and co-workers showed no difference
between arthroscopic irrigation and sham operations of OA
knee joints, nor regarding pain or function [40]. However,
patients in the latter study were predominantly male and
younger than our cohort leading to the thought that only
certain patients may profit from arthroscopic irrigation.
Removing inflamed SF at an early OA stage might inhibit
the start of the self-escalating inflammatory cycle whereas
joint lavage of late-stage OA might have no or only
mild/temporary effects.
Early diagnosis of OA presents another clinical chal-
lenge and is crucial for disease prevention. Conventional
diagnostic tools such as radiographic and magnetic reson-
ance imaging (MRI) showed limited sensitivity or are
time-consuming and expensive [41]. Analysis of cartilage
matrix molecules in body fluids is still only used as
research tool and gene expression profiles in peripheral
blood leukocytes showed ambivalent cytokine levels
[4,42]. Alam and colleagues successfully showed in a
canine animal model that biomarkers in SF such as
tartrate-resistant acid phosphatase, MMP-2, and tissue
inhibitor of MMP-2 can be used for diagnosis of early OA
[43]. Another canine animal model by Garner and
co-workers showed high sensitivity and specificity of
IL-8 and monocyte chemoattractant protein-1 in SF
to surgically-induced OA. Our data show that mRNA
of IL-1β, MMP-1 and -3 in SF is a sensitive indicator for
symptomatic OA [44]. Further research should evaluate
whether these markers are also able to detect early or
non-symptomatic OA and whether they can function as a
prognostic tool.Conclusion
Our findings show that SF of OA patients contains cells
that actively promote inflammation via expression of
proinflammatory mediators and joint-degrading enzymes.
Although origin and type of cells still have to be investi-
gated, this may offer an explanation as to why removal
of OA SF can cause OA symptom relief. Furthermore,
qPCR-based analysis of SF might offer a promising
diagnostic tool and the data presented here lead to
speculation towards potential pharmacologic OA inter-
vention on a biological basis.
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